Strategies to generate highly concentrated HIV-1 vector pseudotypes involving different envelope (Env) proteins including the vesicular stomatitis virus (VSV) G glycoprotein, the Moloney murine leukemia virus (MLV) 4070A amphotropic Env and the rabies G glycoprotein were established. Virus stocks were prepared by transient transfection using standard cell culture media or serum-free media. Such stocks were concentrated 50-to 300-fold by ultracentrifugation or by ultrafiltration using Centricon Plus-80 units yield-
Lentiviral vectors including HIV-1-based vectors are being increasingly used for gene delivery in vitro. They are also promising for long-term gene expression in vivo in cells of the central nervous system, hematopoietic system, retina, muscle and liver, lung and pancreatic islets. 1, 2 Lentivirus-based vectors are traditionally produced by transient cotransfection of human embryonic kidney 293T cells using three to four different plasmids encoding helper (packaging), envelope (Env) and gene transfer functions, respectively. Typical virus titers range from 10 6 to 10 7 transducing units per milliliter. Increased titers can be achieved by physical concentration. Pseudotyped lentiviral particles containing the VSV-G glycoprotein have been shown to be quite stable and to withstand concentration by ultracentrifugation without significant loss in titer, 3, 4 thus opening up the way to generate highly concentrated vector stocks for in vivo applications. Ultracentrifugation protocols to concentrate HIV-1 pseudotypes involving alternative Env proteins have not been described so far, in part because it was assumed that such pseudotypes would be unstable. This was previously observed with MLV-based vectors involving Env proteins other than VSV-G. 5 Alternative concentration protocols were established for HIV-1-based vectors. Reiser et al 6 have developed a facile ultrafiltration procedure to concentrate HIV-1 pseudotypes. Good recoveries were obtained with HIV-1 particles containing VSV-G or the MLV amphotropic Env. This paper documents the fact that HIV-1 vectors pseudotyped with alternative Env proteins including the MLV amphotropic Env and the rabies G glycoprotein retain full infectivity after ultracentrifugation. The paper also extends our original protocol with emphasis on scale-up of vector production, mode of concentration (ultracentrifugation versus ultrafiltration) and composition of the medium (serum-containing media versus protein-free media). A novel 293-based cell line expressing the amphotropic MLV Env protein allowing the generation of high-titer amphotropic HIV-1 pseudotypes is also described.
The influences of time and composition of the cell culture medium on vector production were evaluated first. 293T cells were cotransfected with the previously described HIV-neo⌬E vector 7 encoding G418 resistance together with the C-Help packaging construct 7 and the LTR-G envelope construct encoding VSV-G 6 ( Figure 1 ). Twelve hours later the medium was removed and replaced with DMEM containing 10% fetal bovine serum or with media lacking serum (UltraCULTURE). Media were replaced again 24, 40, 60 and 80 h after initiating transfection and the culture supernatants were collected and frozen immediately. For titration the samples were thawed simultaneously and end point titers (G418-resistant colony-forming units (c.f.u.) per milliliter) were determined on human osteosarcoma (HOS) cells following G418 selection. HOS cells were primarily used because they have been shown in the past to be readily infectable by pseudotyped vectors. 6, 7 The results presented in Figure 2 show that there was an increase in titer up to 40 h in serum-containing and serum-free media with titers reaching 2 × 10 7 c.f.u./ml. Subsequent to that virus production dropped. This was particularly 8 obvious with cells kept in DMEM/10% while cells kept in serum-free UltraCULTURE medium showed a more prolonged phase of virus production. Thus, serum-free media such as UltraCULTURE allow multiple collections for extended periods of time. This is an attractive feature for virus production at a preparative scale. Also, the absence of serum in the final virus preparation may be advantageous in certain circumstances where serum interferes with the physiology of the target cell to be transduced.
To investigate the stability of VSV-G-pseudotyped HIV-1 vector particles during production, the accumulated vector titers in DMEM/10% FBS and in serum-free medium were investigated at 37°C and at 33°C. Transfected cells were incubated at 37°C and 33°C and aliquots of the culture supernatants were collected 40, 60, and 86 h after the start of the transfection and immediately frozen. Media were not changed during collection. All aliquots were thawed simultaneously and end point titers were determined on HOS cells following G418 selection. Titers remained relatively constant (1-2 × 10 7 c.f.u./ml) at 37°C from 40 h up to 86 h in DMEM/10% FBS and in Ultra-CULTURE medium. At 33°C titers in both media reached a plateau at 60 h and remained above 10 7 c.f.u./ml up to 86 h (data not shown). Taken together with the data presented in Figure 2 , these results indicate that HIV-1 vectors pseudotyped with VSV-G are stable for at least 86 h in serum-containing and in serum-free media at 33°C and 37°C.
HIV-1 vector particles pseudotyped with the MLV amphotropic Env have previously been produced using three-component transient transfection protocols with titers around 10 5 transducing units per milliliter. 3, 7 With a view toward increasing the titers of HIV-1 vectors pseudotyped with the amphotropic Env, stable cell lines expressing the 4070A Env protein were generated. 293 Cells were transfected using the the ALF plasmid encoding the 4070A Env 8 and clones were obtained following selection with phleomycin (50 g/ml final concentration). Some of the best clones yielded vector titers up to 3 × 10 6 c.f.u./ml following transient transfection of such clones with the C-Help and HIV-neo⌬E plasmids. These titers are are about five-to 10-fold higher than the ones observed previously.
Increases in viral titers were achieved by concentration of the culture supernatants by ultracentrifugation. Ultracentrifugation protocols to generate high-titer HIV-1 vector stocks pseudotyped with VSV-G have been described before. 3, 4 However, the stability of HIV-1 vectors pseudotyped with alternative Env proteins has not been investigated. The results shown in Table 1 demonstrate that HIV-neo⌬E pseudotypes carrying the MLV 4070A Env or the rabies G glycoprotein could be concentrated some 70-to 100-fold by ultracentrifugation with good recovery as judged from the virus titers. These findings suggest that HIV-1-based vectors pseudotyped with the MLV 4070A amphotropic Env or the rabies G glycoprotein resist inactivation during ultracentrifugation similar to other retroviral vectors pseudotyped with VSV-G. Other HIV-1-based vector constructs also lend themselves to concentration by ultracentrifugation. The NL-EGFP/P vector encoding EGFP was pseudotyped with VSV-G and concentrated about 300-fold using ultracentrifugation. The NL-EGFP/P and HIV-neo⌬E vectors differ in terms of the reporter genes, internal promoters and presence or absence of the tat and rev coding regions (Figure 1a) . It is apparent from the results presented in Figure 3 that unconcentrated vector stocks reached titers between 5 × 10 6 and 1 × 10 7 transducing units per milliliter in T-150 flasks and that subsequent concentration by ultracentrifugation yielded titers above 10 9 transducing units per milliliter. The recovered virus titer after centrifugation was above 90%.
Ultrafiltration was used as an alternative to ultracentrifugation to generate concentrated virus stocks. Centricon Plus-80 units with a 100 kDa molecular weight cut-off filter were used. HIV-neo⌬E vectors pseudotyped with VSV-G, the MLV 4070A Env or the rabies G glycoprotein were prepared in T-75 or T-150 cell culture flasks using Transfections into 293T cells 10 were done in T-150 flasks using 30 ml of DMEM/10% FBS in the presence of chloroquine (25 m final concentration). Thirty micrograms each of helper, Env and vector DNA were combined with 250 mm CaCl 2 in a total volume of 3 ml. An equal volume of 2 × HEPES-buffered saline (HBS) 11 was subsequently added by vortexing. Media were changed 12 h after transfection. Thirty milliliters of virus supernatant were collected 60 h after transfection and filtered through a 0.45 m membrane. Ultracentrifugation (25 000 r.p.m., 15°C, 105 min) was carried out using a Beckman SW28 rotor. Virus titers were determined by limiting dilution in the following way. Target cells were split into sixwell plates the day before infection to give approximately 50% confluence at the time of infection. Infections were performed with serial dilutions of virus stocks in a total of 0.5 ml of medium containing 8 g of polybrene per milliliter. After 3 to 6 h at 37°C, the virus was removed and 2 ml of medium was added and the plates incubated at 37°C for an additional 3 days. The medium was then aspirated, and 2 ml of medium supplemented with G418 (0.35 to 0.5 mg of active drug per milliliter; Life Technologies Inc, Gaithersburg, MD, USA) was placed into each well. The medium was changed every 3 to 4 days, and the colonies were counted on days 10 or 14 after staining with crystal violet (0.2% in 20% ethanol). 15 ml or 30 ml, respectively of DMEM/10% FBS per flask. The cell-free supernatants were then concentrated 60-to 70-fold by ultrafiltration (Table 2) . Surprisingly, the titers increased up to 350-fold. Titers around 5 × 10 7 c.f.u./ml were observed for rabies G pseudotypes and up to 10 9 c.f.u./ml for VSV-G and 4070A pseudotypes. This suggests that the ultrafiltration procedure may have removed an inhibitor of viral infection. Higher than expected virus titers following ultrafiltration were observed before with spleen necrosis virus vector preparations. 9 Ultrafiltration is expected to bypass resuspension problems that are encountered with virus stocks concentrated by ultracentrifugation. However, for in vivo experiments the use of serum-free medium during virus production is recommended in order to avoid serum proteins that tend to accumulate during ultrafiltration.
Figure 3 Production and concentration of vector pseudotypes encoding EGFP. Transfections into 293T cells were carried out as described in the legend to Table 1, but using the NL-EGFP/P vector construct (Figure 1a
A variety of different Env proteins are currently being tested with regard to their capacity to pseudotype lentivi- Transfections into 293T cells were done in T-75 flasks (results presented on first three lines) or T-150 flasks (results presented on bottom line) using 15 ml and 30 ml, respectively, of DMEM/10% FBS in the presence of chloroquine (25 m final concentration). For T-75 flasks 15 g each of helper, Env and vector DNA were combined with 250 mm CaCl 2 in a total volume of 1.5 ml. An equal volume of 2 × HBS was subsequently added by vortexing. For T-150 flasks all volumes were doubled. Sixty milliliters of combined supernatants were collected 60 h after transfection filtered through a 0.45 m membrane and concentrated using Centricon Plus-80 units (Millipore, Bedford, MA, USA) by centrifugation at 1500 r.p.m. for 2-2.5 h at 15°C in a Beckman GPR centrifuge (Beckman Instruments, Palo Alto, CA, USA). Titers were determined as described in the legend to Table 1. ral vectors. The protocols described in this study will be useful to generate high-titer stocks of such pseudotypes.
